Microba Life Sciences Limited (ASX:MAP)

Market Cap	38.36M -49.6%
Revenue (ttm)	14.90M -11.8%
Net Income	-19.75M
EPS	-0.04
Shares Out	608.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	896,444
Open	0.0680
Previous Close	0.0630
Day's Range	0.0630 - 0.0680
52-Week Range	0.0630 - 0.1550
Beta	2.02
Analysts	Strong Buy
Price Target	0.13 (+106.35%)
Earnings Date	Apr 29, 2026

About Microba Life Sciences

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MAP

Financial Performance

In fiscal year 2025, Microba Life Sciences's revenue was 15.67 million, an increase of 29.60% compared to the previous year's 12.09 million. Losses were -14.94 million, -25.07% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for MAP stock is "Strong Buy." The 12-month stock price target is $0.13, which is an increase of 106.35% from the latest price.

Price Target

$0.13

(106.35% upside)

Analyst Consensus: Strong Buy